AMBU B Ambu A/S Class B

AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/23

AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/23

Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix.



PRELIMINARY FINANCIAL HIGHLIGHTS FOR THE FULL FINANCIAL YEAR 2022/23

Last year’s comparative figures are stated in brackets.

  • Revenue was DKK 4,775m (DKK 4,444m), with organic growth of 7.6% (4%), driven by strong growth in Endoscopy Solutions. Reported growth for the year was 7.4% (11%). 
  • Gross margin was 56.8% (57.5%), mainly impacted by a strengthened product mix, driven by Endoscopy Solutions.
  • EBIT before special items was DKK 302m (DKK 122m), corresponding to a margin of 6.3% (2.7%), mainly driven by scale in OPEX.



Based on the preliminary full-year 2023/23 results, Ambu’s organic revenue growth and EBIT margin before special items are as follows:

 Previous outlook9 October 2023
Organic revenue growth6 - 8%7.6%
EBIT margin before special items5 - 6%6.3%



The stated preliminary results for the full financial year 2022/23 are unaudited.

Ambu will release its Annual Report on 8 November 2023.







Ambu A/S

Baltorpbakken 13 2750 Ballerup 

Denmark

Tel.  

CVR no.: 63 64 49 19





CONTACT



Investors 

Anders Hjort 

Head of Investor Relations

 

Media 

Tine Bjørn Schmidt

Head of Corporate Communications







ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.



Attachment



EN
09/10/2023

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
05/08/25 May 8, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

AMBU B AMBU A/S CLASS B
05/07/25 May 7, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
05/07/25 May 7, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
05/06/25 May 6, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK155.00) - Another strong quarter

We forecast Ambu to have another strong quarter, with c14% organic growth (we are above consensus) and continued solid margin progression. Despite tariffs, we expect the company to maintain its full-year guidance, but possibly increase the top-line guidance later in the year. We will also look for comments on the impact of tariffs on margins in the coming years. We reiterate our BUY, but have lowered our target price to DKK155 (165).

AMBU B AMBU A/S CLASS B
05/02/25 May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch